NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

Depressive Disorder, Major Clinical Trial

Official title:

NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02994433
• Other study ID #: 201606120
• Status: Terminated
• Phase: Phase 1
• Start date: January 27, 2017
• Est. completion date: February 28, 2020

Study information

• Verified date: July 2021
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do not respond to these treatments and are referred to as treatment-resistant major depression (TRMD). New treatments for TRMD are needed, and one promising line of research are drugs known as N-methyl-D-aspartate (NMDA) glutamate receptor antagonists. In a recent pilot study, our group demonstrated that the NMDA antagonist nitrous oxide is effective in TRMD. This application proposes to take the next important step in understanding how nitrous oxide exerts its effects in the human brain by using state-of-the-art brain neuroimaging (functional connectivity magnetic resonance imaging) in a group of non-depressed, healthy volunteers and comparing the results to a group of TRMD patients.

This study involves exposing 20 non-depressed healthy participants and 20 TRMD participants to nitrous oxide and a placebo gas, to compare their brain images before and after each of the inhalation sessions. Sessions will be separated by at least one month to prevent treatment effects from carrying over into the following session. All willing and eligible subjects will undergo up to six functional connectivity MRI scans, and two inhalation sessions. Functional imaging in the brain will allow us to trace the interconnections between various parts of the brain, including those involved with emotion and depression.

Other procedures will involve screening materials to ensure safety of the participants before beginning the study (i.e. no MRI scan contraindications) and that subjects meet eligibility criteria to being in the targeted age range, depression/non-depressed state, neurological disorder history, and no medication exclusions.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 49
• Est. completion date: February 28, 2020
• Est. primary completion date: February 28, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Adults 18-65 years of age

• Right-handed

• Controls: Not meet The Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder (MDD) by scoring =7 on the Hamilton Depression Rating Scale (HDRS), 17-item; Treatment-Resistant Major Depression (TRMD) patients: Must meet a =17 score on the HDRS.

• Controls: Must not have any history of depression as determined by reported history and medical record review; TRMD: Documented (chart review) failure to respond to =3-4 adequate dose/duration antidepressant treatments; =1 in the current depressive episode.

• Good command of the English language

Exclusion Criteria:

• Meets criteria for any DSM-IV Axis I diagnosis as documented in medical records and as determined by structured clinical interview (except MDD for the TRMD group)

• Known primary neurological disorders or medical disorders including dementia, stroke, encephalopathy Parkinson's Disease, brain tumors, multiple sclerosis, seizure disorder, severe cardiac or pulmonary disease

• Any central nervous system active medication as determined by study investigator

• Any known disease affecting drug metabolism and excretion (e.g. renal or liver disease) as determined by study investigator

• Left-handedness

• Not eligible for MRI scans (e.g. history of claustrophobia/implanted metal as per MRI Screening Tool)

• Current use of psychotropic medications, antidepressants, or prescription or non-prescription drugs/herbals intended to treat depression or anxiety (control group only)

• Any recent (within past 12 months) history of substance dependence or abuse, determined by reported history or urine drug screen

• Ability to become pregnant and not using effective contraception

• Contraindication against the use of nitrous oxide:

1. Pneumothorax

2. Bowel obstruction

3. Middle ear occlusion

4. Elevated intracranial pressure

5. Chronic cobalamin and/or folate deficiency treated with folic acid or vitamin B12

6. Pregnant patients

7. Breastfeeding women

• Inability to provide informed consent

• Any other factor that in the investigators' judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from clinic).

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Depressive Disorder, Treatment-Resistant
• Disease

Intervention

Drug:
• Nitrous Oxide
Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
• Placebo gas
Placebo gas given at 50% nitrogen [inert]/50% oxygen.

Device:
• MRI
MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of functional connectivity between default mode network of treatment-resistant depressed and non-depressed participants	Functional connectivity is measured between groups after inhaling nitrous oxide/placebo using an individual seed-voxel z map and pared t-test group analysis to identify effects on inter-regional connectivity.	2 hours after inhalation
Primary	Comparison of functional connectivity between affective network of treatment-resistant depressed and non-depressed participants	Functional connectivity is measured between groups after inhaling nitrous oxide/placebo using an individual seed-voxel z map and pared t-test group analysis to identify effects on inter-regional connectivity.	2 hours after inhalation
Primary	Comparison of functional connectivity between cognitive control network of treatment-resistant depressed and non-depressed participants	Functional connectivity is measured between groups after inhaling nitrous oxide/placebo using an individual seed-voxel z map and pared t-test group analysis to identify effects on inter-regional connectivity.	2 hours after inhalation
Primary	Comparison of functional connectivity between dorsal nexus of treatment-resistant depressed and non-depressed participants	Functional connectivity is measured between groups after inhaling nitrous oxide/placebo using an individual seed-voxel z map and pared t-test group analysis to identify effects on inter-regional connectivity.	2 hours after inhalation